Access To HCV Therapies Decreasing Despite Pricing Reductions
Executive Summary
Data presented by Trio Health covering about 15,000 US hepatitis C patients from 2014 to 2016 show that failure to start treatment increased from 8% to 29%. Denials of coverage by private insurers, Medicare and Medicaid are the main reason driving this trend, the data analysis firm contends.
You may also be interested in...
Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV
While a dwindling patient base and pricing pressures are depleting the market opportunity in hepatitis C, Merck's decision also may result from regulatory dialogue potentially delaying the start of a Phase III study.
Gilead Admits It Needs M&A To Resume Growth, But Stays Quiet
Sharply declining HCV sales, three upcoming patent expirations and a lack of near-term pipeline prospects other than HIV candidate bictegravir leave the specialty firm needing to spend some of its gigantic cash reserves on assets to revitalize its portfolio and/or stimulate the R&D engine.
Gilead Offers Split Guidance For HCV; Expects Further Decline In 2017
A 22% decline in hepatitis C sales year-over-year was offset somewhat by a 17% uptick for the HIV franchise, but the virology powerhouse is guiding for continued HCV falloff in 2017.